Forte Biosciences (FBRX) Other Accumulated Expenses (2016 - 2026)
Forte Biosciences (FBRX) reported Other Accumulated Expenses of $82000.0 for Q1 2026, down 25.45% year-over-year from $110000.0 in Q1 2025, and up 925.0% quarter-over-quarter from $8000.0 in Q4 2025.
Forte Biosciences (FBRX) Other Accumulated Expenses (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has 11 years of Other Accumulated Expenses data on file, last reported at $82000.0 in Q1 2026.
- Other Accumulated Expenses for Q1 2026 came in at $82000.0, down 25.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $82000.0 (down 25.45% YoY), and the FY2025 annual result was $8000.0, down 93.94% from the prior year.
- Other Accumulated Expenses advanced to $82000.0 in Q1 2026 per FBRX's latest filing, from $8000.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $141000.0 in Q1 2022 and troughed at $3000.0 in Q4 2023.
- A 5-year average of $54750.0 and a median of $43500.0 in 2022 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses surged 4300.0% in 2024, then slumped 93.94% in 2025.
- A 5-year view of Other Accumulated Expenses shows it stood at $8000.0 in 2022, then sank by 62.5% to $3000.0 in 2023, then surged by 4300.0% to $132000.0 in 2024, then tumbled by 93.94% to $8000.0 in 2025, then surged by 925.0% to $82000.0 in 2026.
- Business Quant data shows FBRX's Other Accumulated Expenses at $82000.0 in Q1 2026, $8000.0 in Q4 2025, and $30000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Forte Biosciences | 70.77 Mn | 12.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 82,000.00 |
| Dec 31, 2025 | 8,000.00 |
| Sep 30, 2025 | 30,000.00 |
| Jun 30, 2025 | 84,000.00 |
| Mar 31, 2025 | 110,000.00 |
| Dec 31, 2024 | 132,000.00 |
| Sep 30, 2024 | 15,000.00 |
| Jun 30, 2024 | 13,000.00 |
| Dec 31, 2023 | 3,000.00 |
| Sep 30, 2023 | 70,000.00 |
| Jun 30, 2023 | 36,000.00 |
| Mar 31, 2023 | 59,000.00 |
| Dec 31, 2022 | 8,000.00 |
| Sep 30, 2022 | 34,000.00 |
| Jun 30, 2022 | 51,000.00 |
| Mar 31, 2022 | 141,000.00 |
| Dec 31, 2021 | 16,000.00 |
| Sep 30, 2021 | 61,000.00 |
| Jun 30, 2021 | 63,000.00 |
| Mar 31, 2021 | 13,000.00 |